Effects of palonosetron on nausea and vomiting induced by multiple-day chemotherapy: A retrospective study

Hirofumi Hamano, Chisato Mitsuhashi, Yoshiko Suzuki, Yoshito Zamami, Kaito Tsujinaka, Naoto Okada, Takahiro Niimura, Tatsuya Hayama, Toru Imai, Shunsuke Ishida, Kumiko Sakamoto, Mitsuhiro Goda, Kenshi Takechi, Kenta Yagi, Masayuki Chuma, Yuya Horinouchi, Kazuaki Shinomiya, Yasumasa Ikeda, Yasushi Kirino, Toshimi NakamuraHiroaki Yanagawa, Yasuhiro Hamada, Keisuke Ishizawa

Research output: Contribution to journalArticlepeer-review

Abstract

Patients who undergo multiple-day chemotherapy sessions experience hard-to-treat nausea and vomiting. Currently, there is no effective standard treatment for this condition. This study compared the preventive effect of first-generation 5-hydroxytryptamine 3 receptor antagonists (5-HT3 RAs) and second-generation 5-HT3 RAs palonosetron in multiple-day chemotherapy-induced nausea and vomiting. The design of this study was a retrospective case-control study of patients who received a five-day cisplatin-based chemotherapy and were treated with aprepitant, dexamethasone, granisetron, and ramosetron or palonosetron. The patients were divided into two groups: patients given granisetron and ramosetron (the first-generation group), and those given palonosetron (palonosetron group). The percentage of patients with a complete response or total control was assessed. They were divided into three phases: 0–216h (overall phase), 0–120h (remedial phase), and 120–216h (after phase). The remedial phase was further divided into 0–24h (early phase) and 24–120h (later phase). Moreover, the nutritional status of each patient was assessed by noting the patients’ total calorie-intake per day and total parenteral nutrition. First-generation 5-HT3 RAs and palonosetron were used for treatment in 18 and 28 patients, respectively. The complete response rate and caloric oral intake of the later phase were higher in the palonosetron group than in the first-generation group. We conclude that palonosetron treatment was more effective than first-generation 5-HT3 RAs in controlling multiple-day chemotherapy-induced nausea and vomiting.

Original languageEnglish
Pages (from-to)478-484
Number of pages7
JournalBiological and Pharmaceutical Bulletin
Volume44
Issue number4
DOIs
Publication statusPublished - 2021
Externally publishedYes

Keywords

  • 5-hydroxytryptamine 3 antagonist
  • Chemotherapy-induced nausea and vomiting
  • Multiple-day chemotherapy
  • Palonosetron
  • Supportive care

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Effects of palonosetron on nausea and vomiting induced by multiple-day chemotherapy: A retrospective study'. Together they form a unique fingerprint.

Cite this